# A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Study · id `cardio:ct-nct07794579` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07794579](<https://clinicaltrials.gov/study/NCT07794579>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07794579

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2001 participants.

## Technical summary

Registry record NCT07794579. Randomized; double masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2029-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2001 participants (planned count; ClinicalTrials.gov record NCT07794579, source copy `cardio:ctgov-nct07794579-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-08-26 (actual) (ClinicalTrials.gov record NCT07794579, source copy `cardio:ctgov-nct07794579-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2029-08 (anticipated) (ClinicalTrials.gov record NCT07794579, source copy `cardio:ctgov-nct07794579-2026-11-05`, retrieved 2026-11-18)
- Completion: 2030-09 (anticipated) (ClinicalTrials.gov record NCT07794579, source copy `cardio:ctgov-nct07794579-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Argentina; China; Czechia; Germany; India; Japan; Mexico; Puerto Rico; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT07794579, source copy `cardio:ctgov-nct07794579-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07794579-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Acronym: ATTAIN-NOW
- Condition: Overweight
- Condition: Prediabetic State
- Condition: Prehypertension
- Condition: Obesity, Abdominal
- Intervention (Drug): Orforglipron
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 95e536c9379a13cb9ded547b1fc4f1cfbcb4aeb9c2358f448194c63a42cb78d8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
